Last $0.62 USD
Change Today -0.0298 / -4.58%
Volume 123.3K
As of 8:10 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

genetic tech ltd-sp adr (GENE) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/23/13 - $3.00
52 Week Low
08/19/14 - $0.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENETIC TECH LTD-SP ADR (GENE)

genetic tech ltd-sp adr (GENE) Related Bloomberg News

View More Bloomberg News

genetic tech ltd-sp adr (GENE) Related Businessweek News

No Related Businessweek News Found

genetic tech ltd-sp adr (GENE) Details

Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of DNA based genetic tests for cancer predisposition, including breast cancer, ovarian cancer, bowel cancer, and uterine cancer; neurogenetic diagnostic assays; and gene testing for gene related disorders. The company also provides DNA based tests comprising antenatal DNA testing, deceased estate DNA testing, DNA profiling, grandparent DNA testing, immigration DNA testing, legal paternity DNA testing, non-legal paternity DNA testing, sibling DNA testing, twins DNA testing, and Y-chromosome DNA testing services to determine parentage or relatedness. In addition, it offers animals’ tests consisting of disease testing, breed identification, coat color, and animal forensic DNA testing. Further, the company is involved in the out-licensing of its non-coding technology; and research and development activities in the field of genetics and related areas. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Founded in 1987

genetic tech ltd-sp adr (GENE) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$223.1K
Senior Vice President Sales & Marketing - Phe...
Total Annual Compensation: A$222.0K
Scientific Director
Total Annual Compensation: A$114.1K
Compensation as of Fiscal Year 2013.

genetic tech ltd-sp adr (GENE) Key Developments

Genetic Technologies Limited Appoints Eutillio Buccilli as Chief Financial Officer, Effective 2 June 2014

Genetic Technologies Limited announced the appointment of Mr. Eutillio Buccilli to the role of Chief Financial Officer, effective 2 June 2014. Mr. Buccilli joins Genetic Technologies after more than 35 years of senior management experience in the financial services, contracting and recruitment, property and retail industries in Australia and the USA.

Genetic Technologies Limited Announces Consolidated Cash Flow Results for the Third Quarter and Nine Months Ended March 31, 2014

Genetic Technologies Limited announced consolidated cash flow results for the third quarter and nine months ended March 31, 2014. For the quarter, the company reported negative net operating cash flows of AUD 2,455,012 and payment for the acquisition of physical non-current assets of AUD 11,828. For the nine months, the company reported negative net operating cash flows of AUD 7,698,315 and payment for the acquisition of physical non-current assets of AUD 27,113.

Genetic Technologies Executes Settlement, Covenant and License Agreement with Promega Corporation

Genetic Technologies Limited reported the execution of a settlement, covenant and license agreement with Promega Corporation. Under this agreement, GTG grants broad rights to Promega in relation to GTG's Intron Sequence Analysis and Genomic Mapping patents. The precise commercial terms of this Agreement are covered by formal confidentiality provisions and cannot be disclosed.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GENE:US $0.62 USD -0.0298

GENE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $57.64 USD -0.35
Bristol-Myers Squibb Co $50.18 USD +0.19
Pfizer Inc $28.92 USD +0.10
Sonic Healthcare Ltd A$17.55 AUD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation GENE Industry Range
No financial data is available for GENE.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENETIC TECH LTD-SP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at